- AN2 Therapeutics ( NASDAQ: ANTX ) has secured a contract valued up to $17.8M from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to advance the development of epetraborole for acute systemic melioidosis.
- The award leverages AN2 Therapeutics expertise and commitment to address urgent unmet global health needs.
- The work could help address U.S. biothreat pathogen.
- The base period contract is $4.3M with additional options that, if exercised, will total $17.8M to support preclinical, Phase 1 studies and other activities to enable advancement of epetraborole into a pivotal Phase 2/3 clinical trial for acute systemic melioidosis.
- AN2 Therapeutics is currently developing epetraborole in an ongoing pivotal Phase 2/3 trial for treatment refractory Mycobacterium avium complex lung disease, the most common form of nontuberculous mycobacterial lung disease.
For further details see:
AN2 Therapeutics secures $17.8M contract from NIH